ReviewFrontiers in bioengineering and biotechnology2026
Hydroxyapatite-based bone repair biomaterials based on clinical heterogeneity: modification strategies, performance regulation, and personalized repair pathways.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The repair of bone defects represents a major clinical challenge in orthopedics, oral and maxillofacial surgery, and trauma surgery. The heterogeneity of their etiology, anatomical sites, local microenvironments, and patients' systemic conditions imposes diverse and sometimes contradictory performance requirements on repair materials. As the primary inorganic component of human bone, hydroxyapatite (HA) is considered an ideal foundational material for bone repair due to its excellent biocompatibility, osteoconductivity, and osteoinductive potential. However, its inherent brittleness, insufficient mechanical strength, and single functionality limit its application in complex clinical scenarios. This article reviews the latest advances in the modification of HA-based materials through strategies such as ion doping, composite reinforcement, structural regulation, and surface functionalization, aiming to precisely modulate their mechanical properties, degradation behavior, osteogenic activity, antibacterial capacity, and pro-vascularization functions. Furthermore, this article provides an in-depth analysis of the heterogeneous characteristics of various clinical bone defect types-including infectious, load-bearing, ischemic (insufficient blood supply), osteoporotic, and post-tumor resection defects-and their differential requirements for material performance. On this basis, a new clinical problem-oriented material design paradigm is proposed, shifting from a "universal" approach to a "personalized" one. This involves a personalized research and development strategy that conducts precise functional integration and performance trade-offs for specific clinical scenarios (e.g., "antibacterial-dominant," "mechanical-bioactive synergy," "osteogenesis/anti-resorption dual regulation," "pro-vascularization induction," and "integrated tumor suppression and repair"), thereby achieving a precise match between material properties and specific clinical needs. Finally, this article discusses the current limitations regarding the standardization of performance evaluation, multi-functional synergistic mechanisms, and clinical translation. It also anticipates future development directions for personalized bone repair materials, including the construction of a multi-scale and multi-dimensional material performance evaluation system, the advancement of "personalized responsive" material development, and the strengthening of clinical translation research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.